

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Complete if Known</i>	
				Application Number	Continuation of 09/993,896
				Filing Date	Herewith
				First Named Inventor	REDMOND
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	1194-282

### U.S. PATENT DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
K	1	6,479,481	B1	STENDEL et al.	11/12/2002

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
	2	9240743		A1	Ed Geistlich Soehne AG fuer Chemische Industrie	01/23/1992	
Examiner Signature	R. Looch				Date Considered	12/7/05	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number	Continuation of 09/993,896
				Filing Date	Herewith
				First Named Inventor	REDMOND
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	1194-282
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
u	3	<b>BRAUMANN, C., et al., "The Influence of Intraoperative Intravenous and Intraperitoneal Application of Taurolidine with Heparin on Subcutaneous and Intraperitoneal Tumor Growth in Laparoscopic Surgery in a Rat Model", Department of Surgery, Humboldt-University of Berlin, Campus Charité Mitte, Schumannstr. 20-21, 10098 Berlin, Germany, April 14th and 15th, 2000, 3 pages.</b>			
n	4	<b>CARTER, S., et al., "Chemotherapy of Cancer", Second Edition, A Wiley Medical Publication, pp. 77-78.</b>			
u	5	<b>FOYE, W., "Cancer Chemotherapeutic Agents", American Chemical Society, Washington, DC, 1995, pp. 50-55.</b>			
h	6	<b>JACOBI, C.A., et al., "Intraperitoneal Instillation of Taurolidine and Heparin for the Prevention of intraperitoneal Tumor Growth and Trocar Metastases in Laparoscopic Surgery in a Rat Model", Langebecks Arch Chir, (1997) 382 Suppl. 1: S31-S36.</b>			
u	7	<b>JACOBI, C.A., et al., "Influence of Different Gases and Intraperitoneal Instillation of Antiadherent or Cytotoxic Agents on Peritoneal Tumor Cell Growth and Implantation with Laparoscopic Surgery in a Rat Model", Surg Endosc, (1999) 13:1021-1025.</b>			
r	8	<b>JACOBI, C.A., et al., "New Therapeutic Strategies to Avoid Intra- and Extraperitoneal Metastases during Laparoscopy: Results of a Tumor Model in the Rat", Dig Surg, 1999; 16:393-399.</b>			
u	9	<b>JACOBI, C.A., et al., "Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model", The American Journal of Surgery, (1997) Vol. 174, pp.359-363.</b>			
	10	<del><b>MONSON, J.R.T., et al., "Preliminary Evidence that Taurolidine is Anti-neoplastic as well as Anti-endotoxin and Anti-microbial", Br. J. Surg., A711, Vol. 77, No. 6, June 1990.</b></del>			
	11	<del><b>MONSON, J.R.T., et al., "Taurolidine As An Anti-neoplastic Agent: A Previously Undiscovered role?", Br. J. Surg., 1432, Vol. 77, No. 12, December 1990.</b></del>			
	12	<del><b>WEBERCHOCK, T. et al., "Efficacy of Systemic Taurolidine Application in the Treatment of Liver Metastases in a Rat Model", Dept. of General and Vascular Surgery, Johann-Wolfgang Goethe-University, Frankfurt/Main, Germany, p. 41.</b></del>			
Examiner Signature				Date Considered	12/7/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*Complete if Known*

Application Number 10/660,798

Filing Date September 12, 2003

First Named Inventor REDMOND

Group Art Unit 1614

Examiner Name Goldman

Sheet

1

of

2

Attorney Docket Number 1194-282

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
✓	1	EP	1 066 830	A2	Ed. Geistlich Sohne AG fur Chemische Industrie	01/10/2001	
h	2	WO	92/00743	A1	Ed. Geistlich Sohne AG fur Chemische Industrie	01/23/1992	

Examiner  
Signature

*Alloch*

Date  
Considered

12/7/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.



\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.